PharmVar GeneFocus: <i>CYP3A5</i>

202242 citationsReviewbronze Open Access

Authors

Cristina Rodríguez‐Antona · Spanish National Cancer Research Centre

Jessica Savieo · Allen Institute for Cell Science

Volker M. Lauschke · Karolinska Institutet

Katrin Sangkuhl · Stanford University

Britt I. Drögemöller · Research Institute in Oncology and Hematology

Daqing Wang · University of Florida

Ron H. N. van Schaik

Abstract

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Topics & Keywords

Pharmacogenetics and Drug Metabolism Pharmacological Effects and Toxicity Studies Drug-Induced Hepatotoxicity and Protection

Publication Details

Published in: Clinical Pharmacology & Therapeutics

Volume 112, Issue 6, pp. 1159-1171

DOI: 10.1002/cpt.2563

Field-Weighted Citation Impact: 6.87

Command Palette

PharmVar GeneFocus: <i>CYP3A5</i>

Authors

Abstract

Topics & Keywords

Publication Details